Momekort (Mometasone Furoate Monohydrate)

Mometasone furoate monohydrate is a synthetic glucocorticoid that binds to glucocorticoid receptors inside nasal mucosal cells. The activated receptor complex alters gene transcription, suppressing the production of inflammatory cytokines and mediators, which reduces swelling, mucus production, and irritation in the nasal passages.

The specific dosing regimen for Momekort is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and clinical response. Common practice may involve one spray per nostril once daily, but the exact dose and frequency should always follow the prescriber’s instructions.

Safety data for mometasone furoate monohydrate in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss them with the patient. If treatment is necessary, it should be used under close medical supervision.

To order Momekort, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Momekort (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate and budesonide. Compared with some alternatives, it may provide longer duration of action, allowing once‑daily dosing, while maintaining a favorable safety profile when used as directed.

Store Momekort at room temperature, preferably below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture, direct sunlight, and excessive heat. Do not freeze the product, and keep it out of reach of children.

Before first use, gently prime the spray by pressing the actuator several times until a fine mist appears. Tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril with a finger, and spray while breathing in gently. Repeat in the other nostril if prescribed, and avoid blowing the nose for a few minutes afterward.

Serious but rare risks include adrenal suppression with prolonged high‑dose use, development of cataracts or glaucoma, severe nasal septum perforation, and opportunistic fungal infections of the nasal cavity. Patients should report persistent nosebleeds, visual changes, or signs of infection promptly to their healthcare provider.

Momekort should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and those receiving systemic corticosteroids at doses that could lead to excess glucocorticoid exposure.